{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:27:28Z","timestamp":1759336048739,"version":"build-2065373602"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00393-025-01700-5","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:09:55Z","timestamp":1756728595000},"page":"621-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erfahrungen nach CD19-CAR-T-Zell-Therapie bei Nicht-SLE-Kollagenosen","Experiences after CD19-CAR T-cell therapy in non-SLE connective tissue diseases"],"prefix":"10.1007","volume":"84","author":[{"given":"Wolfgang","family":"Merkt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanns-Martin","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"1","key":"1700_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41584-023-01044-x","volume":"20","author":"V Liakouli","year":"2024","unstructured":"Liakouli\u00a0V, Ciancio\u00a0A, Del Galdo\u00a0F, Giacomelli\u00a0R, Ciccia\u00a0F (2024) Systemic sclerosis interstitial lung disease: unmet needs and potential solutions. Nat Rev Rheumatol 20(1):21\u201332. https:\/\/doi.org\/10.1038\/s41584-023-01044-x (Epub 2023 Nov 3, PMID: 37923862)","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1700_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2015.00496","volume":"29","author":"L Soto","year":"2015","unstructured":"Soto\u00a0L, Ferrier\u00a0A, Aravena\u00a0O, Fonseca\u00a0E, Berendsen\u00a0J, Biere\u00a0A, Bueno\u00a0D, Ramos\u00a0V, Aguill\u00f3n\u00a0JC, Catal\u00e1n\u00a0D (2015) Systemic sclerosis patients present alterations in the expression of molecules involved in B\u2011cell regulation. Front Immunol 29(6):496. https:\/\/doi.org\/10.3389\/fimmu.2015.00496 (PMID: 26483788, PMCID: PMC4586944)","journal-title":"Front Immunol"},{"issue":"1","key":"1700_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","volume":"54","author":"T Matsushita","year":"2006","unstructured":"Matsushita\u00a0T, Hasegawa\u00a0M, Yanaba\u00a0K, Kodera\u00a0M, Takehara\u00a0K, Sato\u00a0S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54(1):192\u2013201. https:\/\/doi.org\/10.1002\/art.21526 (PMID: 16385515)","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1700_CR4","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/ar2965","volume":"12","author":"S Bosello","year":"2010","unstructured":"Bosello\u00a0S, De Santis\u00a0M, Lama\u00a0G, Span\u00f2\u00a0C, Angelucci\u00a0C, Tolusso\u00a0B, Sica\u00a0G, Ferraccioli\u00a0G (2010) B\u00a0cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL\u20116 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12(2):R54. https:\/\/doi.org\/10.1186\/ar2965 (Epub 2010 Mar 25, PMID: 20338043, PMCID: PMC2888203)","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1700_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler\u00a0JHW, Gy\u00f6rfi\u00a0AH, Ramanujam\u00a0M, Whitfield\u00a0ML, K\u00f6nigshoff\u00a0M, Lafyatis\u00a0R (2019) Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 15(12):705\u2013730. https:\/\/doi.org\/10.1038\/s41584-019-0322-7 (Epub 2019 Nov 11, PMID: 31712723)","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1700_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/annrheumdis-2014-206965","volume":"75","author":"H St\u00f6rch","year":"2016","unstructured":"St\u00f6rch\u00a0H, Zimmermann\u00a0B, Resch\u00a0B, Tykocinski\u00a0LO, Moradi\u00a0B, Horn\u00a0P, Kaya\u00a0Z, Blank\u00a0N, Rehart\u00a0S, Thomsen\u00a0M, Lorenz\u00a0HM, Neumann\u00a0E, Tretter\u00a0T (2016) Activated human B\u00a0cells induce inflammatory fibroblasts with cartilage-destructive properties and become functionally suppressed in return. Ann Rheum Dis 75(5):924\u2013932. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206965 (Epub 2015 May 18, PMID: 25985971)","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1700_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1046\/j.1523-1747.2003.12097.x","volume":"120","author":"S Sato","year":"2003","unstructured":"Sato\u00a0S, Hayakawa\u00a0I, Hasegawa\u00a0M, Fujimoto\u00a0M, Takehara\u00a0K (2003) Function blocking autoantibodies against matrix metalloproteinase\u20111 in patients with systemic sclerosis. J\u00a0Invest Dermatol 120(4):542\u2013547. https:\/\/doi.org\/10.1046\/j.1523-1747.2003.12097.x (PMID: 12648215)","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1700_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00281-015-0513-5","volume":"37","author":"J G\u00fcnther","year":"2015","unstructured":"G\u00fcnther\u00a0J, Rademacher\u00a0J, van Laar\u00a0JM, Siegert\u00a0E, Riemekasten\u00a0G (2015) Functional autoantibodies in systemic sclerosis. Semin Immunopathol 37(5):529\u2013542. https:\/\/doi.org\/10.1007\/s00281-015-0513-5 (Epub 2015 Aug 21, PMID: 26292621)","journal-title":"Semin Immunopathol"},{"issue":"Suppl\u00a03","key":"1700_CR9","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.5152\/eurjrheum.2020.19131","volume":"7","author":"D Benfaremo","year":"2020","unstructured":"Benfaremo\u00a0D, Svegliati Baroni\u00a0S, Manfredi\u00a0L, Moroncini\u00a0G, Gabrielli\u00a0A (2020) Putative functional pathogenic autoantibodies in systemic sclerosis. Eur J Rheumatol 7(Suppl\u00a03):S181\u2013S186. https:\/\/doi.org\/10.5152\/eurjrheum.2020.19131 (Epub 2020 Oct 1, PMID: 33164733, PMCID: PMC7647689)","journal-title":"Eur J Rheumatol"},{"issue":"2","key":"1700_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1586\/1744666X.2016.1115717","volume":"12","author":"MO Becker","year":"2016","unstructured":"Becker\u00a0MO, Riemekasten\u00a0G (2016) Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Expert Rev Clin Immunol 12(2):115\u2013135. https:\/\/doi.org\/10.1586\/1744666X.2016.1115717 (Epub 2015 Dec 2, PMID: 26558747)","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"1700_CR11","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3899\/jrheum.150844","volume":"43","author":"J Bauhammer","year":"2016","unstructured":"Bauhammer\u00a0J, Blank\u00a0N, Max\u00a0R, Lorenz\u00a0HM, Wagner\u00a0U, Krause\u00a0D, Fiehn\u00a0C (2016) Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a\u00a0marker for severity and treatment response. J\u00a0Rheumatol 43(8):1566\u20131574. https:\/\/doi.org\/10.3899\/jrheum.150844 (Epub 2016 Jun 1, PMID: 27252419)","journal-title":"J Rheumatol"},{"issue":"7","key":"1700_CR12","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata\u00a0S, Yoshizaki\u00a0A, Oba\u00a0K, Kashiwabara\u00a0K, Ueda\u00a0K, Uemura\u00a0Y, Watadani\u00a0T, Fukasawa\u00a0T, Miura\u00a0S, Yoshizaki-Ogawa\u00a0A, Asano\u00a0Y, Okiyama\u00a0N, Kodera\u00a0M, Hasegawa\u00a0M, Sato\u00a0S (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a\u00a0double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3(7):e489\u2013e497. https:\/\/doi.org\/10.1016\/S2665-9913(21)00107-7 (Epub 2021 May 26, PMID: 38279402)","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1700_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher\u00a0TM, Tudor\u00a0VA, Saunders\u00a0P, Gibbons\u00a0MA, Fletcher\u00a0SV, Denton\u00a0CP, Hoyles\u00a0RK, Parfrey\u00a0H, Renzoni\u00a0EA, Kokosi\u00a0M, Wells\u00a0AU, Ashby\u00a0D, Szigeti\u00a0M, Molyneaux\u00a0PL, RECITAL Investigators (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a\u00a0double-blind, double-dummy, randomised, controlled, phase\u00a02b\u00a0trial. Lancet Respir Med 11(1):45\u201354. https:\/\/doi.org\/10.1016\/S2213-2600(22)00359-9 (Epub 2022 Nov 11, PMID: 36375479)","journal-title":"Lancet Respir Med"},{"issue":"24","key":"1700_CR14","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar\u00a0JM, Farge\u00a0D, Sont\u00a0JK, Naraghi\u00a0K, Marjanovic\u00a0Z, Larghero\u00a0J, Schuerwegh\u00a0AJ, Marijt\u00a0EW, Vonk\u00a0MC, Schattenberg\u00a0AV, Matucci-Cerinic\u00a0M, Voskuyl\u00a0AE, van de Loosdrecht\u00a0AA, Daikeler\u00a0T, K\u00f6tter\u00a0I, Schmalzing\u00a0M, Martin\u00a0T, Lioure\u00a0B, Weiner\u00a0SM, Kreuter\u00a0A, Deligny\u00a0C, Durand\u00a0JM, Emery\u00a0P, Machold\u00a0KP, Sarrot-Reynauld\u00a0F, Warnatz\u00a0K, Adoue\u00a0DF, Constans\u00a0J, Tony\u00a0HP, Del Papa\u00a0N, Fassas\u00a0A, Himsel\u00a0A, Launay\u00a0D, Monaco\u00a0LA, Philippe\u00a0P, Qu\u00e9r\u00e9\u00a0I, Rich \u00c9, Westhovens\u00a0R, Griffiths\u00a0B, Saccardi\u00a0R, van den Hoogen\u00a0FH, Fibbe\u00a0WE, Soci\u00e9\u00a0G, Gratwohl\u00a0A, Tyndall\u00a0A, EBMT\/EULAR Scleroderma Study Group (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a\u00a0randomized clinical trial. JAMA 311(24):2490\u20132498. https:\/\/doi.org\/10.1001\/jama.2014.6368 (PMID: 25058083)","journal-title":"JAMA"},{"issue":"1","key":"1700_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan\u00a0KM, Goldmuntz\u00a0EA, Keyes-Elstein\u00a0L, McSweeney\u00a0PA, Pinckney\u00a0A, Welch\u00a0B, Mayes\u00a0MD, Nash\u00a0RA, Crofford\u00a0LJ, Eggleston\u00a0B, Castina\u00a0S, Griffith\u00a0LM, Goldstein\u00a0JS, Wallace\u00a0D, Craciunescu\u00a0O, Khanna\u00a0D, Folz\u00a0RJ, Goldin\u00a0J, St Clair\u00a0EW, Seibold\u00a0JR, Phillips\u00a0K, Mineishi\u00a0S, Simms\u00a0RW, Ballen\u00a0K, Wener\u00a0MH, Georges\u00a0GE, Heimfeld\u00a0S, Hosing\u00a0C, Forman\u00a0S, Kafaja\u00a0S, Silver\u00a0RM, Griffing\u00a0L, Storek\u00a0J, LeClercq\u00a0S, Brasington\u00a0R, Csuka\u00a0ME, Bredeson\u00a0C, Keever-Taylor\u00a0C, Domsic\u00a0RT, Kahaleh\u00a0MB, Medsger\u00a0T, Furst\u00a0DE, SCOT Study Investigators (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N\u00a0Engl J Med 378(1):35\u201347. https:\/\/doi.org\/10.1056\/nejmoa1703327 (PMID: 29298160, PMCID: PMC5846574)","journal-title":"N Engl J Med"},{"issue":"1","key":"1700_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur\u00a0C, Eckstein\u00a0M, Velden\u00a0J, Rauber\u00a0S, Bergmann\u00a0C, Auth\u00a0J, Bucci\u00a0L, Corte\u00a0G, Hagen\u00a0M, Wirsching\u00a0A, Grieshaber-Bouyer\u00a0R, Reis\u00a0P, Kittan\u00a0N, Wacker\u00a0J, Rius Rigau\u00a0A, Ramming\u00a0A, D\u2019Agostino\u00a0MA, Hartmann\u00a0A, M\u00fcller\u00a0F, Mackensen\u00a0A, Bozec\u00a0A, Schett\u00a0G, Raimondo\u00a0MG (2025) CD19-CAR T\u2011cell therapy induces deep tissue depletion of B\u00a0cells. Ann Rheum Dis 84(1):106\u2013114. https:\/\/doi.org\/10.1136\/ard-2024-226142 (Epub 2025 Jan 2, PMID: 39874224)","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1700_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","volume":"29","author":"O Benveniste","year":"2016","unstructured":"Benveniste\u00a0O, Stenzel\u00a0W, Allenbach\u00a0Y (2016) Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol 29(5):662\u2013673. https:\/\/doi.org\/10.1097\/WCO.0000000000000376 (PMID: 27538058)","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"1700_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","volume":"19","author":"T Khoo","year":"2023","unstructured":"Khoo\u00a0T, Lilleker\u00a0JB, Thong\u00a0BY, Leclair\u00a0V, Lamb\u00a0JA, Chinoy\u00a0H (2023) Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol 19(11):695\u2013712. https:\/\/doi.org\/10.1038\/s41584-023-01033-0 (Epub 2023 Oct 6, PMID: 37803078)","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1700_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg\u00a0IE, Fujimoto\u00a0M, Vencovsky\u00a0J, Aggarwal\u00a0R, Holmqvist\u00a0M, Christopher-Stine\u00a0L, Mammen\u00a0AL, Miller\u00a0FW (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7(1):86. https:\/\/doi.org\/10.1038\/s41572-021-00321-x (PMID: 34857798)","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"1700_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11926-024-01164-7","volume":"26","author":"J Musai","year":"2024","unstructured":"Musai\u00a0J, Mammen\u00a0AL, Pinal-Fernandez\u00a0I (2024) Recent updates on the pathogenesis of inflammatory myopathies. Curr Rheumatol Rep 26(12):421\u2013430. https:\/\/doi.org\/10.1007\/s11926-024-01164-7 (Epub 2024 Sep 24, PMID: 39316320, PMCID: PMC11527972)","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"1700_CR21","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/ard-2024-225773","volume":"83","author":"I Pinal-Fernandez","year":"2024","unstructured":"Pinal-Fernandez\u00a0I, Mu\u00f1oz-Braceras\u00a0S, Casal-Dominguez\u00a0M, Pak\u00a0K, Torres-Ruiz\u00a0J, Musai\u00a0J, Dell\u2019Orso\u00a0S, Naz\u00a0F, Islam\u00a0S, Gutierrez-Cruz\u00a0G, Cano\u00a0MD, Matas-Garcia\u00a0A, Padrosa\u00a0J, Tobias-Baraja\u00a0E, Garrabou\u00a0G, Aldecoa\u00a0I, Espinosa\u00a0G, Simeon-Aznar\u00a0CP, Guillen-Del-Castillo\u00a0A, Gil-Vila\u00a0A, Trallero-Aragu\u00e1s\u00a0E, Christopher-Stine\u00a0L, Lloyd\u00a0TE, Liewluck\u00a0T, Naddaf\u00a0E, Stenzel\u00a0W, Greenberg\u00a0SA, Grau\u00a0JM, Selva-O\u2019Callaghan\u00a0A, Milisenda\u00a0JC, Mammen\u00a0AL (2024) Pathological autoantibody internalisation in myositis. Ann Rheum Dis 83(11):1549\u20131560. https:\/\/doi.org\/10.1136\/ard-2024-225773 (PMID: 38902010, PMCID: PMC11493519)","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1700_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/ard-2023-223873","volume":"82","author":"I Pinal-Fernandez","year":"2023","unstructured":"Pinal-Fernandez\u00a0I, Milisenda\u00a0JC, Pak\u00a0K, Mu\u00f1oz-Braceras\u00a0S, Casal-Dominguez\u00a0M, Torres-Ruiz\u00a0J, Dell\u2019Orso\u00a0S, Naz\u00a0F, Gutierrez-Cruz\u00a0G, Duque-Jaimez\u00a0Y, Matas-Garcia\u00a0A, Padrosa\u00a0J, Garcia-Garcia\u00a0FJ, Guitart-Mampel\u00a0M, Garrabou\u00a0G, Trallero-Aragu\u00e1s\u00a0E, Walitt\u00a0B, Paik\u00a0JJ, Albayda\u00a0J, Christopher-Stine\u00a0L, Lloyd\u00a0TE, Grau-Junyent\u00a0JM, Selva-O\u2019Callaghan\u00a0A, Mammen\u00a0AL (2023) Transcriptional derepression of CHD4\/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies. Ann Rheum Dis 82(8):1091\u20131097. https:\/\/doi.org\/10.1136\/ard-2023-223873 (Epub 2023 May 2, PMID: 37130727, PMCID: PMC11611052)","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"1700_CR23","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal\u00a0R, Charles-Schoeman\u00a0C, Schessl\u00a0J, Bata-Cs\u00f6rg\u0151\u00a0Z, Dimachkie\u00a0MM, Griger\u00a0Z, Moiseev\u00a0S, Oddis\u00a0C, Schiopu\u00a0E, Vencovsk\u00fd\u00a0J, Beckmann\u00a0I, Clodi\u00a0E, Bugrova\u00a0O, Dank\u00f3\u00a0K, Ernste\u00a0F, Goyal\u00a0NA, Heuer\u00a0M, Hudson\u00a0M, Hussain\u00a0YM, Karam\u00a0C, Magnolo\u00a0N, Nelson\u00a0R, Pozur\u00a0N, Prystupa\u00a0L, S\u00e1rdy\u00a0M, Valenzuela\u00a0G, van der Kooi\u00a0AJ, Vu\u00a0T, Worm\u00a0M, Levine\u00a0T, ProDERM Trial Group (2022) Trial of intravenous immune globulin in dermatomyositis. N\u00a0Engl J Med 387(14):1264\u20131278. https:\/\/doi.org\/10.1056\/NEJMoa2117912 (PMID: 36198179)","journal-title":"N Engl J Med"},{"issue":"1","key":"1700_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/RHU.0000000000002151","volume":"31","author":"LO Rojas","year":"2025","unstructured":"Rojas\u00a0LO, Ramsubeik\u00a0K, Sanchez-Ramos\u00a0L, Motilal\u00a0S, Singh\u00a0JA, Kaeley\u00a0GS (2025) Rituximab treatment in adult patients with idiopathic inflammatory myositis: a\u00a0systematic review and meta-analysis. J\u00a0Clin Rheumatol 31(1):33\u201339. https:\/\/doi.org\/10.1097\/RHU.0000000000002151 (Epub 2024 Nov 11, PMID: 39527803)","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"1700_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis\u00a0CV, Reed\u00a0AM, Aggarwal\u00a0R, Rider\u00a0LG, Ascherman\u00a0DP, Levesque\u00a0MC, Barohn\u00a0RJ, Feldman\u00a0BM, Harris-Love\u00a0MO, Koontz\u00a0DC, Fertig\u00a0N, Kelley\u00a0SS, Pryber\u00a0SL, Miller\u00a0FW, Rockette\u00a0HE, RIM Study Group (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a\u00a0randomized, placebo-phase trial. Arthritis Rheum 65(2):314\u2013324. https:\/\/doi.org\/10.1002\/art.37754 (PMID: 23124935, PMCID: PMC3558563)","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1700_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann\u00a0C, M\u00fcller\u00a0F, Distler\u00a0JHW, Gy\u00f6rfi\u00a0AH, V\u00f6lkl\u00a0S, Aigner\u00a0M, Kretschmann\u00a0S, Reimann\u00a0H, Harrer\u00a0T, Bayerl\u00a0N, Boeltz\u00a0S, Wirsching\u00a0A, Taubmann\u00a0J, R\u00f6sler\u00a0W, Spriewald\u00a0B, Wacker\u00a0J, Atzinger\u00a0A, Uder\u00a0M, Kuwert\u00a0T, Mackensen\u00a0A, Schett\u00a0G (2023) Treatment of a\u00a0patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T\u00a0cells. Ann Rheum Dis 82(8):1117\u20131120. https:\/\/doi.org\/10.1136\/ard-2023-223952 (Epub 2023 May 5, PMID: 37147112, PMCID: PMC10359520)","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1700_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt\u00a0W, Freitag\u00a0M, Claus\u00a0M, Kolb\u00a0P, Falcone\u00a0V, R\u00f6hrich\u00a0M, Rodon\u00a0L, Deicher\u00a0F, Andreeva\u00a0I, Tretter\u00a0T, Tykocinski\u00a0LO, Blank\u00a0N, Watzl\u00a0C, Schmitt\u00a0A, Sauer\u00a0T, M\u00fcller-Tidow\u00a0C, Polke\u00a0M, Heu\u00dfel\u00a0CP, Dreger\u00a0P, Lorenz\u00a0HM, Schmitt\u00a0M (2024) Third-generation CD19. CAR-T\u00a0cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis 83(4):543\u2013546. https:\/\/doi.org\/10.1136\/ard-2023-225174 (PMID: 38135464, PMCID: PMC10958299)","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"1700_CR28","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMc2403705","volume":"390","author":"W Merkt","year":"2024","unstructured":"Merkt\u00a0W, Lorenz\u00a0HM, Schmitt\u00a0M (2024) CAR T\u2011cell therapy in autoimmune disease. N\u00a0Engl J Med 390(17):1628\u20131629. https:\/\/doi.org\/10.1056\/NEJMc2403705 (PMID: 38692297)","journal-title":"N Engl J Med"},{"issue":"18","key":"1700_CR29","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang\u00a0X, Wu\u00a0X, Tan\u00a0B, Zhu\u00a0L, Zhang\u00a0Y, Lin\u00a0L, Xiao\u00a0Y, Sun\u00a0A, Wan\u00a0X, Liu\u00a0S, Liu\u00a0Y, Ta\u00a0N, Zhang\u00a0H, Song\u00a0J, Li\u00a0T, Zhou\u00a0L, Yin\u00a0J, Ye\u00a0L, Lu\u00a0H, Hong\u00a0J, Cheng\u00a0H, Wang\u00a0P, Li\u00a0W, Chen\u00a0J, Zhang\u00a0J, Luo\u00a0J, Huang\u00a0M, Guo\u00a0L, Pan\u00a0X, Jin\u00a0Y, Ye\u00a0W, Dai\u00a0L, Zhu\u00a0J, Sun\u00a0L, Zheng\u00a0B, Li\u00a0D, He\u00a0Y, Liu\u00a0M, Wu\u00a0H, Du\u00a0B, Xu\u00a0H (2024) Allogeneic CD19-targeted CAR\u2011T therapy in patients with severe myositis and systemic sclerosis. Cell 187(18):4890\u20134904.e9. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027 (Epub 2024 Jul 15, PMID: 39013470)","journal-title":"Cell"},{"issue":"1","key":"1700_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-024-03451-1","volume":"26","author":"M Claus","year":"2024","unstructured":"Claus\u00a0M, Freitag\u00a0M, Ewald\u00a0M, Rodon\u00a0L, Deicher\u00a0F, Watzl\u00a0C, Kolb\u00a0P, Lorenz\u00a0HM, Schmitt\u00a0M, Merkt\u00a0W (2024) Immunological effects of CD19. CAR-T\u00a0cell therapy in systemic sclerosis: an extended case study. Arthritis Res Ther 26(1):211. https:\/\/doi.org\/10.1186\/s13075-024-03451-1 (PMID: 39673062, PMCID: PMC11639114)","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1700_CR31","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth\u00a0J, M\u00fcller\u00a0F, V\u00f6lkl\u00a0S, Bayerl\u00a0N, Distler\u00a0JHW, Tur\u00a0C, Raimondo\u00a0MG, Chenguiti Fakhouri\u00a0S, Atzinger\u00a0A, Coppers\u00a0B, Eckstein\u00a0M, Liphardt\u00a0AM, B\u00e4uerle\u00a0T, Tascilar\u00a0K, Aigner\u00a0M, Kretschmann\u00a0S, Wirsching\u00a0A, Taubmann\u00a0J, Hagen\u00a0M, Gy\u00f6rfi\u00a0AH, Kharboutli\u00a0S, Krickau\u00a0T, Dees\u00a0C, Sp\u00f6rl\u00a0S, Rothe\u00a0T, Harrer\u00a0T, Bozec\u00a0A, Grieshaber-Bouyer\u00a0R, Fuchs\u00a0F, Kuwert\u00a0T, Berking\u00a0C, Horch\u00a0RE, Uder\u00a0M, Mackensen\u00a0A, Schett\u00a0G, Bergmann\u00a0C (2025) CD19-targeting CAR T\u2011cell therapy in patients with diffuse systemic sclerosis: a\u00a0case series. Lancet Rheumatol 7(2):e83\u2013e93. https:\/\/doi.org\/10.1016\/S2665-9913(24)00282-0 (Epub 2024 Nov 11, PMID: 39542003)","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"1700_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0F, Taubmann\u00a0J, Bucci\u00a0L, Wilhelm\u00a0A, Bergmann\u00a0C, V\u00f6lkl\u00a0S, Aigner\u00a0M, Rothe\u00a0T, Minopoulou\u00a0I, Tur\u00a0C, Knitza\u00a0J, Kharboutli\u00a0S, Kretschmann\u00a0S, Vasova\u00a0I, Spoerl\u00a0S, Reimann\u00a0H, Munoz\u00a0L, Gerlach\u00a0RG, Sch\u00e4fer\u00a0S, Grieshaber-Bouyer\u00a0R, Korganow\u00a0AS, Farge-Bancel\u00a0D, Mougiakakos\u00a0D, Bozec\u00a0A, Winkler\u00a0T, Kr\u00f6nke\u00a0G, Mackensen\u00a0A, Schett\u00a0G (2024) CD19 CAR T\u2011cell therapy in autoimmune disease\u2014a case series with follow-up. N\u00a0Engl J Med 390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917 (PMID: 38381673)","journal-title":"N Engl J Med"},{"key":"1700_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S2213-2600(25)00159-6","volume":"13","author":"W Merkt","year":"2025","unstructured":"Merkt\u00a0W, R\u00f6hrich\u00a0M, Mavriopoulou\u00a0E, St\u00fctz\u00a0AN, Distler\u00a0JHW, Schmitt\u00a0A, Polke\u00a0M, Heu\u00dfel\u00a0CP, Schmitt\u00a0M, Lorenz\u00a0HM (2025) Lancet Respir Med 13:651-654","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1700_CR34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00259-023-06564-y","volume":"51","author":"Y Mori","year":"2024","unstructured":"Mori\u00a0Y, Kramer\u00a0V, Novruzov\u00a0E, Mamlins\u00a0E, R\u00f6hrich\u00a0M, Fern\u00e1ndez\u00a0R, Amaral\u00a0H, Soza-Ried\u00a0C, Monje\u00a0B, Sabbagh\u00a0E, Florenzano\u00a0M, Giesel\u00a0FL, Undurraga \u00c1 (2024) Initial results with (18F)FAPI-74 PET\/CT in idiopathic pulmonary fibrosis. Eur J Nucl Med Mol Imaging 51(6):1605\u20131611. https:\/\/doi.org\/10.1007\/s00259-023-06564-y (Epub 2023 Dec 20, PMID: 38117298, PMCID: PMC11043111)","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1700_CR35","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","volume":"3","author":"C Bergmann","year":"2021","unstructured":"Bergmann\u00a0C, Distler\u00a0JHW, Treutlein\u00a0C, Tascilar\u00a0K, M\u00fcller\u00a0AT, Atzinger\u00a0A, Matei\u00a0AE, Knitza\u00a0J, Gy\u00f6rfi\u00a0AH, L\u00fcck\u00a0A, Dees\u00a0C, Soare\u00a0A, Ramming\u00a0A, Sch\u00f6nau\u00a0V, Distler\u00a0O, Prante\u00a0O, Ritt\u00a0P, G\u00f6tz\u00a0TI, K\u00f6hner\u00a0M, Cordes\u00a0M, B\u00e4uerle\u00a0T, Kuwert\u00a0T, Schett\u00a0G, Schmidkonz\u00a0C (2021) 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a\u00a0single-centre, pilot study. Lancet Rheumatol 3(3):e185\u2013e194. https:\/\/doi.org\/10.1016\/S2665-9913(20)30421-5 (Epub 2021 Jan 25, PMID: 38279381)","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"1700_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold\u00a0AM, Allanore\u00a0Y, Alves\u00a0M, Brunborg\u00a0C, Air\u00f3\u00a0P, Ananieva\u00a0LP, Czirj\u00e1k\u00a0L, Guiducci\u00a0S, Hachulla\u00a0E, Li\u00a0M, Mihai\u00a0C, Riemekasten\u00a0G, Sfikakis\u00a0PP, Kowal-Bielecka\u00a0O, Riccardi\u00a0A, Distler\u00a0O, EUSTAR collaborators (2021) Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 80(2):219\u2013227. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217455 (Epub 2020 Sep 28, PMID: 32988845, PMCID: PMC7815627)","journal-title":"Ann Rheum Dis"},{"key":"1700_CR37","unstructured":"Pecher et\u00a0al., EULAR Rheumatology Open 2025, in press"},{"issue":"3","key":"1700_CR38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal\u00a0R, Bandos\u00a0A, Reed\u00a0AM, Ascherman\u00a0DP, Barohn\u00a0RJ, Feldman\u00a0BM, Miller\u00a0FW, Rider\u00a0LG, Harris-Love\u00a0MO, Levesque\u00a0MC, RIM Study Group, Oddis\u00a0CV (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66(3):740\u2013749. https:\/\/doi.org\/10.1002\/art.38270 (PMID: 24574235, PMCID: PMC3987896)","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"1700_CR39","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1093\/rheumatology\/kead010","volume":"62","author":"T Oliveira","year":"2023","unstructured":"Oliveira\u00a0T, Y\u0131ld\u0131r\u0131m\u00a0R, Deakin\u00a0C, Isenberg\u00a0D (2023) Rituximab in myositis: Where are we now? A\u00a0survey of current usage. Rheumatology (Oxford) 62(7):e211\u2013e212. https:\/\/doi.org\/10.1093\/rheumatology\/kead010 (PMID: 36622027, PMCID: PMC10824550)","journal-title":"Rheumatology (Oxford)"},{"issue":"10379","key":"1700_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller\u00a0F, Boeltz\u00a0S, Knitza\u00a0J, Aigner\u00a0M, V\u00f6lkl\u00a0S, Kharboutli\u00a0S, Reimann\u00a0H, Taubmann\u00a0J, Kretschmann\u00a0S, R\u00f6sler\u00a0W, Manger\u00a0B, Wacker\u00a0J, Mougiakakos\u00a0D, Jabari\u00a0S, Schr\u00f6der\u00a0R, Uder\u00a0M, Roemer\u00a0F, Kr\u00f6nke\u00a0G, Mackensen\u00a0A, Schett\u00a0G (2023) CD19-targeted CAR T\u00a0cells in refractory antisynthetase syndrome. Lancet 401(10379):815\u2013818. https:\/\/doi.org\/10.1016\/S0140-6736(23)00023-5 (Epub 2023 Feb 15, PMID: 36930673)","journal-title":"Lancet"},{"issue":"24","key":"1700_CR41","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher\u00a0AC, Hensen\u00a0L, Klein\u00a0R, Schairer\u00a0R, Lutz\u00a0K, Atar\u00a0D, Seitz\u00a0C, Stanger\u00a0A, Schneider\u00a0J, Braun\u00a0C, Schmidt\u00a0M, Horger\u00a0M, Bornemann\u00a0A, Faul\u00a0C, Bethge\u00a0W, Henes\u00a0J, Lengerke\u00a0C (2023) CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154\u20132162. https:\/\/doi.org\/10.1001\/jama.2023.8753 (PMID: 37367976, PMCID: PMC10300719)","journal-title":"JAMA"},{"key":"1700_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03718-3","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller\u00a0F, Wirsching\u00a0A, Hagen\u00a0M, V\u00f6lkl\u00a0S, Tur\u00a0C, Raimondo\u00a0MG, Taubmann\u00a0J, Bucci\u00a0L, Zhang\u00a0L, Kretschmann\u00a0S, Aigner\u00a0M, Eckstein\u00a0M, Sp\u00f6rl\u00a0S, Kharboutli\u00a0S, B\u00f6ltz\u00a0S, Atzinger\u00a0A, Munoz\u00a0L, Schett\u00a0G, Mackensen\u00a0A, Grieshaber-Bouyer\u00a0R (2025) BCMA-CAR T\u2011cells in a\u00a0patient with relapsing idiopathic inflammatory myositis after CD19-CAR T\u2011cells. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03718-3 (PMID: 40245922)","journal-title":"Nat Med"},{"issue":"11","key":"1700_CR43","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","volume":"32","author":"J Volkov","year":"2024","unstructured":"Volkov\u00a0J, Nunez\u00a0D, Mozaffar\u00a0T, Stadanlick\u00a0J, Werner\u00a0M, Vorndran\u00a0Z, Ellis\u00a0A, Williams\u00a0J, Cicarelli\u00a0J, Lam\u00a0Q, Furmanak\u00a0T, Schmitt\u00a0C, Hadi-Nezhad\u00a0F, Thompson\u00a0D, Miller\u00a0C, Little\u00a0C, Chang\u00a0D, Basu\u00a0S (2024) Case study of CD19 CAR T therapy in a\u00a0subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase\u00a0I\/II trial. Mol Ther 32(11):3821\u20133828. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.009 (Epub 2024 Sep 7, PMID: 39245937, PMCID: PMC11573600)","journal-title":"Mol Ther"},{"issue":"10","key":"1700_CR44","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.42933","volume":"76","author":"R Nicolai","year":"2024","unstructured":"Nicolai\u00a0R, Merli\u00a0P, Alvarez\u00a0MP, Bracaglia\u00a0C, Del Bufalo\u00a0F, Marasco\u00a0E, Caiello\u00a0I, Prencipe\u00a0G, Algeri\u00a0M, Cefalo\u00a0MG, Becilli\u00a0M, Quintarelli\u00a0C, Sinibaldi\u00a0M, Hanssens\u00a0L, De Benedetti\u00a0F, Locatelli\u00a0F (2024) Autologous CD19-targeting CAR T cells in a\u00a0patient with refractory juvenile dermatomyositis. Arthritis Rheumatol 76(10):1560\u20131565. https:\/\/doi.org\/10.1002\/art.42933 (Epub 2024 Jul 31, PMID: 38924652)","journal-title":"Arthritis Rheumatol"},{"key":"1700_CR45","doi-asserted-by":"publisher","unstructured":"Taubmann J et al. (2025) Effizienz, Langzeitverlauf und Sicherheit der CD19-CAR-T-Zelltherapie beim Systemischen Lupus Erythematodes. Z Rheumatol. https:\/\/doi.org\/10.1007\/s00393-025-01705-0","DOI":"10.1007\/s00393-025-01705-0"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01700-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01700-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01700-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:06:29Z","timestamp":1759313189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01700-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1700"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01700-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"5 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"W.\u00a0Merkt hat Beratungshonorare, Vortragshonorare, Unterst\u00fctzung f\u00fcr Tagungen und\/oder Reisen und\/oder Honorare von Kyverna, Lilly, Boehringer Ingelheim, BMS und Galapagos sowie Drittmittel von ArgenX, Evotec und BMS erhalten. J.\u00a0Henes hat Beratungshonorare, Honorare und Unterst\u00fctzung f\u00fcr Tagungen von BMS, Janssen-Cilag, Miltenyi und Novartis erhalten. C.\u00a0Bergmann hat Vortragshonorare von Novartis erhalten. H.-M.\u00a0Lorenz hat Zusch\u00fcsse und\/oder Beratungshonorare und\/oder Reisekostenzusch\u00fcsse von Novartis, BMS, Gilead\/Galapagos und Janssen-Cilag erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}